Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-05-28
1995-07-04
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514 50, A61K 31425
Patent
active
054300452
ABSTRACT:
The present invention provides a method for reducing, or preventing, bone marrow hypoplasia in a patient at risk of, or having, same. To this end, when a glutathione intracellular stimulator is administered to such a patient, the risk of bone marrow hypoplasia is reduced or prevented. In an embodiment, the composition for stimulating the intracellular glutathione levels comprises L-2-oxothiazolidine-4-carboxylate.
REFERENCES:
patent: 2712202 (1955-07-01), Hosler et al.
patent: 3737536 (1973-06-01), Sagner et al.
patent: 3755578 (1973-08-01), McFarland et al.
patent: 4175130 (1979-11-01), Yamanaka et al.
patent: 4335210 (1982-07-01), Meister et al.
patent: 4338315 (1982-07-01), Paget et al.
patent: 4398026 (1983-08-01), Takano
patent: 4420479 (1983-12-01), Morwick et al.
patent: 4434158 (1984-02-01), Meister
patent: 4438124 (1984-03-01), Meister
patent: 4563471 (1986-01-01), Satzinger et al.
patent: 4647453 (1987-03-01), Meisner
patent: 4647571 (1987-03-01), Meister
patent: 4665082 (1987-05-01), Meister et al.
patent: 4710489 (1987-12-01), Meister
patent: 4752618 (1988-07-01), Mascioli et al.
patent: 4775675 (1988-10-01), Gyorgydeak et al.
patent: 4780475 (1988-10-01), Cerra et al.
patent: 4784685 (1988-11-01), Meister
patent: 4791125 (1988-12-01), Clark
patent: 4798835 (1989-01-01), Krupp et al.
patent: 4839387 (1989-07-01), Poli
patent: 4868114 (1989-09-01), Nagasawa et al.
patent: 4879370 (1989-11-01), Meister
patent: 4963577 (1990-10-01), Schorlemmer et al.
patent: 5002953 (1991-03-01), Hindley
patent: 5028627 (1991-07-01), Kilbourn et al.
patent: 5039609 (1991-08-01), Klein
patent: 5053387 (1991-10-01), Alexander
patent: 5055446 (1991-10-01), Alexander et al.
patent: 5089268 (1992-02-01), Katz
patent: 5095027 (1992-03-01), Goldberg et al.
patent: 5158883 (1992-10-01), Griffith
patent: 5208249 (1993-05-01), Rowe et al.
patent: 5214062 (1993-05-01), Mark et al.
Bounous, et al., Immunoenhancing Property of Dietary Whey Protein in Mice: Role of Glutathoine, Clinical Investigative Medicine, vol. 12, No. 4, pp. 154-161 (1989).
Bone, et al., Definitions for Sepsis and Organ Failure, Critical Care Medicine, 1992, vol. 20, No. 6, pp. 724-725.
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee, American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis, Critical Care Medicine, Jun. 1992, vol. 20, No. 6, pp. 864-874.
Kilbourn, et al., Inhibition of Interleukin-1-.alpha.-Induced nitric Oxide Synthase in Vascular Smooth Muscle and Full Reversal of Interleukin-1-.alpha. Induced Hypotension by N.sup..omega. -Amino-L-Arginine, Journal of the National Cancer Institute, Jul. 1, 1992, vol. 84, No. 13, pp. 1008-1016.
Osol, et al., EDs., Remington's Pharmaceutical Sciences, 1980, Sixteenth Edition.
W. Lucht et al, Prevention of Release of Granulocyte Aggregants into Sheep Lung Lymph Following Endotoxemia by N-Acetylcysteine, The American Journal of the Medical Sciences, vol. 294, No. 3, Sep. 1987, pp. 161-167.
G. Bernard et al, Effect of N-Acetylcysteine on the Pulmonary Response to Endotoxin in the Awake Sheep and Upon In Vitro Granulocyte Function, J. Clin. Invest., vol. 73, Jun. 1984, pp. 1772-1784.
A. Cantin et al, Normal Alveolar Epithelial Lining Fluid Contains High Levels of Glutathione, pp. 152-157. (1987).
L. Smith et al, Effect of Fasting on Hyperoxic Lung Injury in Mice, Am. Rev. Respir. Dis. 1990; 141:141-149.
J. Strausz et al, Oxygen Radical Production by Alveolar Inflammatory Cells in Idiopathic Pulmonary Fibrosis, Am. Rev. Respir. Dis. 1990; 141:124-128.
A. Cantin et al, Glutathione Deficiency in the Epithelial Lining Fluid of the Lower Respiratory Tract in Idiopathic Pulmonary Fibrosis, Am. Rev. Respir. Dis. 1989; 139:370-372.
Guarding Against Cellular Glutathione Deficiency, Nutrition Reviews, vol. 48, No. 9, Sep. 1990, pp. 346-348.
A. Cantin et al, Oxidants, Antioxidants and the Pathogenesis of Emphysema, Eur. J. Respir. Dis (1985) 66, Suppl. 139, pp. 7-17.
I. Cotgreave et al, Lung and Systemic Thiol Homeostasis During an Acute Lung Inflammation in the Rat, Toxicology, 50 (1988), pp. 331-343.
J. Sun et al, Effects of Buthionine Sulfoximine on the Development of Ozone-Induced Pulmonary Fibrosis, Experimental and Molecular Pathology 49 (1988), pp. 254-266.
S. Baldwin et al, Oxidant Activity in Expired Breath of Patients with Adult Respiratory Distress Syndrome, The Lancet, Jan. 4, 1986, pp. 11-14.
M. F. Tsan et al, Enhancement of Intracellular Glutathione Protects Endothelial Cells Against Oxidant Damage, Biochemical and Biophysical Research Communications, vol. 127, No. 1, Feb. 28, 1985, pp. 270-276.
M. F. Tsan et al, L-2--Oxothiazolidine-4-Carboxylate Protects Endothelial Cells Against Hyperocia-Induced Injury, Inflammation, vol. 12, No. 2, 1988, pp. 113-121.
P. H. S. Sporn et al, Complex Effects of In Vitro Hyperoxia on Alveolar Macrophage Arachidonic Acid Metabolism, American Journal of Respiratory Cell and Molecular Biology, vol. 2, No. 1, Jan. 1990, pp. 81-90.
M. A. Passero et al, L-2-Oxothiazolidine-4-Carboxylic Acid Increases Glutathione in Mouse Lung, A. Rev. Respir. Dis., vol. 133, 1986, p. A395.
Uhlig, et al., Glutathione Enhancement in Various Mouse Organs and Protection by Glutathione Isopropyl Ester Against liver Injury, Jun. 15, 1990, p. 1877-.
Bellin, et al., Purification of Glycosaminoglycens from Bovine Follicular Fluid, J. Dairy Sci., Nov. 9, 1987, vol. 70, pp. 1913-1919.
Calvin, et al., Estimation and Manipulation of Glutathione Levels in Prepuberal Mouse Ovaries and Ova: Relevance to Sperm Nucleus Transformation in the Fertilized Egg, Gamete Research, 1986, vol. 14, pp. 165-275.
Gordon, et al., Applications of Micromanipulation to Human in Vitro Fertilization, Journal of In Vitro Fertilization and Embryo Transfer, 1988, vol. 5, No. 2, pp. 57-60.
Perreault, et al., Importance of Glutathione in the Acquisition and Maintenance of Sprem Nuclear Decondensing Activity in Maturing Hamster Oocytes, Developmental Biology, 1988, vol. 125, pp. 181-186.
Perreault, et al., The Timing of Hamster Sperm Nuclear Decondensation and Male Pronucleus Formation is Related to Sperm Nuclear Disulfide Bond Content, Biology of Reproduction, 1987, vol. 36, pp. 239-244.
Perreault, et al., The Role of Disulfide Bond Reduction During Mammalian Sperm Nuclear Decondensation in Vivo, Developmental Biology, 1984, vol. 101, pp. 160-167.
Reyes, et al., Heparin and Glutathione: Physiological Decondensing Agents of Human Sperm Nuclei, Gamete Research, 1989, vol. 23, pp. 39-47.
Zirkin, et al., In Vitro and In Vivo Studies of Mammalian Sperm Nuclear Decondensation, Gamete Research, 1985, vol. 11, pp. 349-365.
Shapiro, The Control of Oxidant Stress at Fertilization, Science, Apr. 26, 1991, pp. 533-536.
Oeriu, et al., 4-Thiazolidinecarboxylic Acids for Live-Stock Raising, Ger. Offen, Oct. 22, 1970, 17 pages.
Slaweta, et al., The Effect of Glutathione on the Motility and Fertility of Frozen Bull Sperm, Amin. Reprod. Sci., 1987, vol. 13, No. 4, pp. 249-253.
Perreault, et al., Importance of Glutathione In the Acquisition And Maintenance of Sprem Nuclear Decondensing Activity In Maturing Hamster Oocytes, Dev. Biol., 1988, vol. 125, No. 1, pp. 181-186.
Lassalle, et al., Relationship Between Fertilizing Ability of Frozen Human Spermatozoa and Capacity for Heparin Binding and Nuclear Decondensation, J. Reprod. Fertil, 1992, vol. 95, No. 2, pp. 313-324.
Wellman, et al., Radioprotection by glutathione ester: Transport of glutathione ester into human lymphoid cells and fibroblasts, Proc. Natl. Acad. Sci. USA, 1984, vol. 81, pp. 4732-4735.
Martenson, et al., Glutathione metabolism in the lung: Inhibition of its synthesis leads to lamellar body and mitochondrial defects, Proc. Natl. Acad. Sci. USA, 1989, vol. 86, pp. 5296-5300.
Roberts, et al., Prodrugs of L-Cysteine as Protective Agents against Acetaminophen-Induced Hepatotoxicity. 2-(Polyhydroxyalkyl)- and 2-(Polyacetoxyalkyl)thiazolidine-4(R)-carboxylic Acids, J. Med. Chem
Goldberg Dennis I.
Pace Gary
White Randy D.
Wilson Daniel M.
Free Radical Sciences, Inc.
Raymond Richard L.
LandOfFree
Method of reducing or preventing bone marrow hypoplasia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of reducing or preventing bone marrow hypoplasia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of reducing or preventing bone marrow hypoplasia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-760366